Sanofi slides J&J’s E. coli vaccine into late-stage portfolio, betting $175M cash on development, commercialization pact
Sanofi has added a late-stage candidate to its vaccine franchise, paying J&J’s Janssen $175 million upfront to partner on a shot that will protect people from extraintestinal pathogenic E. coli.
Janssen began a Phase III trial of the vaccine in 2021. It will now co-fund R&D costs with Sanofi, which is bringing its manufacturing and commercialization operations to the table.
Under CEO Paul Hudson, Sanofi has spotlighted vaccines as a key part of its R&D strategy, with a goal to bring in more than €10 billion ($10.48 billion) in vaccine sales by 2030. At a recent investor event, Jean-François Toussaint, Sanofi’s global head of vaccines R&D, said the French company now has “the largest development toolbox in the industry.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.